Johnson & Johnson and Legend Biotech have received an unexpectedly early boost for their CAR-T drug, Carvykti, in the shape of a leaked abstract for theh CARTITUDE-4 study showing it can cut risk of tumor progression or death by an impressive 74% compared with standard therapy.
That backs up belief that it will outperform its fellow BCMA targeting rival, Bristol Myers Squibb’s Abecma. Both products...